Clinical Trial Update: Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety of BG9588 (anti-CD40L antibody) compared with standard treatment in kidney transplantation; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• BG9588

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Kidney Transplantation | Phase 2 | Status: COMPLETED